PhysioGenixChronic Disease Research Blog

At PhysioGenix, we pride ourselves on continued expansion and expertise in cardiovascular research. With our newly acquired SonoScape S8 color Doppler ultrasound machine, we now hold the capability of capturing accurate, high resolution ultrasound images that impress on our already thorough cardiovascular research applications.

The SonoScape S8 is leading the charge of transportable high resolution ultrasound instruments with advanced M-mode imaging technologies capable of measuring:

• Cardiac Output
• Heart Rate
• LVEDD and LVESD
• PWT and SWT

Superior quality 4D cardiac imaging is now accessible and affordable at PhysioGenix, a world leader in preclinical research services.

For more information please contact us as www.physiogenix.com.

PhysioGenix experienced a tremendous year through the completion of a new research facility, addition of capabilities and record high sales.

Milwaukee, WI (PRWEB) March 23, 2011 – PhysioGenix, already a leader in customer focused contract research, expanded their research facilities, capabilities and research models in 2010. “We experienced tremendous growth in 2010 and anticipate additional growth in 2011,” stated PhysioGenix’s Director of Sales Darin Evans.

PhysioGenix was a winner of Companies to Watch for 2010 by the Wisconsin Entrepreneur Network (WEN) with support from the Wisconsin Department of Commerce and the Division of Entrepreneurship and Economic Development at the University of Wisconsin-Extension in association with the Edward Lowe Foundation to celebrate second-stage entrepreneurial companies. PhysioGenix proved that they deserved the award when they posted record high sales numbers while expanding the company during an economic recession.

One of the largest changes in 2010 was the completion of a new facility in December. The new facility has allowed PhysioGenix to streamline processes and cut costs, which the company is passing onto their clients. Furthermore, the new facilities enabled PhysioGenix to expand their capabilities and research models.

PhysioGenix is known for their excellence in diabetes and metabolic research. During the course of 2010, PhysioGenix expanded their capabilities to include cardiovascular studies. The company saw success over the course of the year and began to build a name for themselves in the field prompting further addition of new internal capabilities such as cardiovascular ultrasound imaging.

Last year also saw PhysioGenix continue their expansion of research models. Previously the company focused on rat studies. In 2010 PhysioGenix brought on a mouse expert and began selling mouse studies. PhysioGenix’s success with multiple mouse models has lead the company to dedicate an entire portion of their new lab facilities to mouse research.

PhysioGenix focuses on providing better customer service, coupled with accurate and reliable lab data that they present to their clients in near-real time. CEO Dr. Brian Curry explains, “Clients we work with come back for numerous studies because they state PhysioGenix provides a level of communication that is difficult to find with other preclinical CROs.”

Although 2010 was an enormous success for PhysioGenix, Dr. Curry is focused on the future, “We are positioned very well to take advantage of an improved economic environment in 2011 and this translates directly into more jobs, which is a good thing for all of us.”

To learn more about PhysioGenix go to www.physiogenix.com.

PhysioGenix, a diabetes and cardiovascular Preclinical Contract Research Organization, donates money to the American Red Cross to aid in the Japan earthquake and Pacific tsunami relief effort.

Milwaukee, WI (PRWEB) March 20, 2011 — PhysioGenix has donated to the American Red Cross to help provide relief for the recent earthquake and tsunami victims. PhysioGenix has been in e-mail contact with several of their Japanese colleagues who have informed them that they and their families are all right. “It feels like we need to do more than check in on our colleagues and end an e-mail with ‘you are in our thoughts and prayers” said PhysioGenix’s CEO Brian Curry.

Japan was struck with an awful disaster at the end of last week with a 9.0 MW earthquake devastating many areas. It was the largest earthquake in the history of Japan and the fourth largest ever in the world. The aftermath of the earthquake continues to wreck Japan as they have been plagued with over a hundred aftershocks, a 6.6 MW earthquake, tsunamis, explosions and state of emergency issues with their nuclear power plants. Japanese Prime Minister Naoto Kan said that “in the 65 years after the end of World War II, this is the toughest and the most difficult crisis for Japan.”

“We have many scientific colleagues and clients from Japan and felt it was necessary to do what we could,” said Dr. Curry. “We are very privileged to work everyday with our clients on treatments of diabetes and cardiovascular disorders that will eventually help mankind.” Some of the drug compounds PhysioGenix tests may take another 10 years before commercialization but the payoff to mankind is well worth the wait. The employees at PhysioGenix are patient and do not mind the long timeline because of high payoff, “however, sometimes you feel the need to help now,” stated Yvette Harrington, Science Liaison for PhysioGenix. The company felt this was one of those times. “Many of our employees have stood at the lab bench with international graduate students, post-docs and professors over the course of their careers and education. We have made good friends and conducted great scientific research together and knew that we could not sit idly by while Japan was dealing with a disaster of this magnitude,” said Dr. Curry.

PhysioGenix likes to live by a phrase they picked up from Mavericks at Work by Taylor and LaBarre, which is ‘build a company that works and work for a company that matters.’ The employees at PhysioGenix agree, helping the Japanese victims matters. “When you donate to quality organizations such as the American Red Cross you know that your money is directly helping people today,” said Dr. Curry. PhysioGenix would also like to ask other scientific based companies to follow suite.